{"DataElement":{"publicId":"2195044","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Lymphedema Fibrosis Grade","preferredDefinition":"in CTC category Lymphatics, assessment of the severity of a lymphedema-related fibrosis adverse event using a graded scale.","longName":"CTC_AE_LYMPH_FIB_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2195042","version":"2","preferredName":"Common Toxicity Criteria Adverse Event Lymphedema Fibrosis","preferredDefinition":"information related to the CTC adverse event of lymphedema-related fibrosis.","longName":"CTC_AE_LYMPH_FIB","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2660695","version":"1","preferredName":"Lymphedema Fibrosis","preferredDefinition":"Edema due to obstruction of lymph vessels or disorders of the lymph nodes.:The growth of fibrous tissue.","longName":"C3207:C3044","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphedema","conceptCode":"C3207","definition":"Excess fluid collection in tissues, causing swelling. It is the result of obstruction of lymphatic vessels or lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fibrosis","conceptCode":"C3044","definition":"The formation of fibrous tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E73C82-C99D-5882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2045A13-872A-ADB5-E040-BB89AD4374D9","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-11-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2195043","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Lymphedema Fibrosis Grade","preferredDefinition":"in CTC category Lymphatics, assessment of the severity of a lymphedema-related fibrosis adverse event using a graded scale.","longName":"CTC_AE_LYMPH_FIB_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECED83FD-D1E5-0D50-E034-0003BA3F9857","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Minimal to moderate redundant soft tissue, unresponsive to elevation or compression, with moderately firm texture or spongy feel","ValueMeaning":{"publicId":"2572625","version":"1","preferredName":"Minimal to moderate redundant soft tissue, unresponsive to elevation or compression, with moderately firm texture or spongy feel","longName":"2572625","preferredDefinition":"Minimal to moderate redundant soft tissue, unresponsive to elevation or compression, with moderately firm texture or spongy feel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8BE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"SHIDED","dateModified":"2005-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECED83FD-D1E8-0D50-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Marked increase in density and firmness, with or without tethering","ValueMeaning":{"publicId":"2572626","version":"1","preferredName":"Marked increase in density and firmness, with or without tethering","longName":"2572626","preferredDefinition":"Marked increase in density and firmness, with or without tethering","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8BF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"SHIDED","dateModified":"2005-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECED83FD-D1EC-0D50-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Very marked density and firmness with tethering affecting >=40% of the edematous area","ValueMeaning":{"publicId":"2572627","version":"1","preferredName":"Very marked density and firmness with tethering affecting >=40% of the edematous area","longName":"2572627","preferredDefinition":"Very marked density and firmness with tethering affecting >=40% of the edematous area","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E8C0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"SHIDED","dateModified":"2005-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECED83FD-D1F0-0D50-E034-0003BA3F9857","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECEE7794-E6F0-0CC1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Lymphedema-","type":"Preferred Question Text","description":"CTC Adverse Event Lymphedema-related fibrosis Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Lymphedema-related fibrosis Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ECEE7969-1614-0D52-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-01-05","modifiedBy":"ALAIS","dateModified":"2011-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}